Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04052230
Other study ID # 38RC19.142
Secondary ID 2019-A01273-54
Status Completed
Phase
First received
Last updated
Start date October 13, 2019
Est. completion date April 19, 2022

Study information

Verified date May 2023
Source University Hospital, Grenoble
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main objective is to evaluate the evolution of the thickness of the diaphragm (during the first week of treatment) by VA ECMO in the resuscitation patients. The comprehension of the mechanisms involved in the diaphragm ailment will identify modifiable factors that lead to muscle degradation and thus to the deterioration of patients' prognosis.


Description:

The evolution of diaphragm muscle thickness is described in human resuscitation under mechanical ventilation, but the incidence, causes and functional impact have not been studied in patients undergoing cardiopulmonary bypass ECMO (extra-corporeal membrane oxygenation) veno-arterial (VA). More generally, the muscular mechanisms of dyspnea in cases of acute cardiac dysfunction are not known. The evolution of the diaphragmatic thickness in intensive care has been described during prolonged stay in intensive care and from the initial phase of septic status. It is associated with dyspnea, weaning delay of mechanical ventilation and impact on patient outcomes. The atrophy of the diaphragm muscle is related to both loss of function and loss of muscle performance. The same is true for hypertrophy that is caused by overuse of the muscle and also causes loss of function. Decreased cardiac muscle performance may require both cardiac assistance and respiratory assistance. Cardiac and respiratory dysfunction may complicate withdrawal of respiratory assistance and extracorporeal circulatory support devices. These two supports, respiratory and circulatory support, make it possible to mitigate the insufficiency of the systemic flow, the oxygenation and the purification of the CO2. Respiratory assistance is known to influence the diaphragmatic function. The role of muscle pump function in the weaning process of the ECMO, however, remains largely unknown. Ultrasound is used in the patient's bed in daily practice to measure cardiac function, the study of vessels but also the diaphragm muscle. It allows to study the trophicity of the diaphragm and these efforts via its contraction. The hypothesis that there is muscular involvement of the diaphragm in this measurable condition by ultrasound method can be formulated. No study has systematically explored the existence of diaphragmatic atrophy under VA ECMO. The influence of cardiac and respiratory assistance is not known. The purpose of this study is to provide a description of the diaphragm physiology of patients treated with VA ECMO. It is to evaluate the evolution of the trophicity of the diaphragm muscle in intensive care. Secondly, to evaluate the factors that influence it at the time of weaning. In this study it's planed to include a cohort of patients with a longitudinal evaluation of the thickness of the diaphragm during a cardiogenic shock under ECMO, and an evaluation of the influence of ECMO parameters and ventilation on the diaphragm.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 19, 2022
Est. primary completion date February 18, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient hospitalized in intensive care - Patient under veno-arterial ECMO - Non-opposition of the patient or relatives - Affiliation to a health insurance Exclusion Criteria: - Subject under guardianship or subject deprived of liberty - Pregnant or lactating woman

Study Design


Related Conditions & MeSH terms

  • Diaphragm
  • Extracorporeal Membrane Oxygenation Complication

Intervention

Other:
ultrasound measure
Admission to the intensive care unit, and setting up an ECMO Daily monitoring from D1 to D7, follow up at D60

Locations

Country Name City State
France CHU Grenoble Alpes Grenoble

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the evolution of the trophicity of the diaphragm muscle during the first week of treatment with VA ECMO in patients in intensive care. Evaluation of the trophicity of the diaphragm muscle at the end of the expiration from the first day in the intensive care unit after the ECMO implementation until the D7 of the hospitalization with ultrasound. A change greater than 10% of the thickness will define three groups of patients (loss of thickness, stability and thickness gain). The first day that this value is reached will determine the allocation in one or the other group. Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the evolution of the performance of the diaphragm muscle in patients in intensive care. Measurement of the thickening fraction of the diaphragm. Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the evolution of respiratory physiological variables and the diaphragm evolution in patients in intensive care. Measurement of the daily evolution of tidal volume during ultrasound collection Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the evolution of respiratory physiological variables and the diaphragm evolution in patients in intensive care. Measurement of the daily evolution of respiratory rate during ultrasound collection Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the evolution of respiratory physiological variables and the diaphragm evolution in patients in intensive care. Measurement of the daily evolution of pulse oximetry during ultrasound collection Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the evolution of respiratory physiological variables and the diaphragm evolution in patients in intensive care. Measurement of the daily evolution of occlusion pressure at 100ms (P0.1)during ultrasound collection Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the evolution of respiratory physiological variables and the diaphragm evolution in patients in intensive care. Measurement of the daily evolution of maximum inspiratory pressure (MIP) during ultrasound collection Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the evolution of respiratory physiological variables and the diaphragm evolution in patients in intensive care. Measurement of the daily evolution of SNIFF test during ultrasound collection Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily ventilatory mode Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily tidal volume Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily respiratory rate Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily positive expiratory pressure Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily plateau pressure Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily motor pressure Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily transpulmonary pressure Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily oesophageal pressure Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive care Measurement of the daily O2 inspired fraction. Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the impact of ECMO parameters and the diaphragm evolution in patients in intensive care Measurement of the daily the daily blood flow Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the impact of ECMO parameters and the diaphragm evolution in patients in intensive care Measurement of the daily the daily sweep rate Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the impact of ECMO parameters and the diaphragm evolution in patients in intensive care Measurement of the daily the daily oxygenation Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the impact of ECMO parameters and the diaphragm evolution in patients in intensive care Measurement of the daily percentage of the theoretical flow Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the impact of ECMO parameters and the diaphragm evolution in patients in intensive care Measurement of the daily duration of ECMO Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the impact of ECMO parameters and the diaphragm evolution in patients in intensive care Measurement of the daily the success of weaning. Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the link between the associated organ failures and the diaphragm evolution in patients in intensive care The daily change in the incidence of diaphragmatic dysfunction defined by the diaphragm thickening fraction <20% during a maximal inspiratory test to J7. The daily collection of hemodynamic variables during the diaphragmatic ultrasound collection including an evaluation of the visual LVEF. Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7
Secondary To evaluate the impact of the diaphragm evolution on the future of the patient in intensive care: weaning of the assistances, survivals.and the diaphragm Measurement of the survival Day 60
Secondary To evaluate the impact of the diaphragm evolution on the future of the patient in intensive care: weaning of the assistances, survivals.and the diaphragm Measurement of the length of stay in intensive care unit Day 60
Secondary To evaluate the impact of the diaphragm evolution on the future of the patient in intensive care: weaning of the assistances, survivals.and the diaphragm Measurement of the failure of extubation Day 60
Secondary To evaluate the impact of the diaphragm evolution on the future of the patient in intensive care: weaning of the assistances, survivals.and the diaphragm Measurement of the number of days without mechanical ventilation Day 60
See also
  Status Clinical Trial Phase
Recruiting NCT05486559 - The ECMO-Free Trial N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Not yet recruiting NCT05306392 - Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation N/A
Active, not recruiting NCT02280460 - ECMO: Optimization of Its Use
Completed NCT02271126 - TEG Anticoagulation Monitoring During ECMO Phase 1
Recruiting NCT05444764 - PREdiCtIon of Weanability, Survival and Functional outcomEs After ECLS
Completed NCT03659513 - The Effect of ECMO on the Pharmacokinetics of the Drugs and Their Clinical Efficacy
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Completed NCT05948332 - Definition and Management of Right Ventricular Injury in Adult Patients Receiving Extracorporeal Membrane Oxygenation
Recruiting NCT04273607 - Anticoagulation-free VV ECMO for Acute Respiratory Failure Phase 2/Phase 3
Not yet recruiting NCT04956497 - Registry Study of Extracorporeal Cardiopulmonary Resuscitation (eCPR) in China
Terminated NCT04524585 - Partial Neuromuscular Blockade in Acute Respiratory Distress Syndrome N/A
Completed NCT04620005 - Impact of Extra Corporal Membrane Oxygenation Services on Burnout Development in Intensive Care Units.
Recruiting NCT05721105 - Evaluation of Long-term Quality of Life in Children Supported With ExtraCorporeal Membrane Oxygenation (ECMO)
Recruiting NCT05796557 - ECMO Hemostatic Transfusions in Children Phase 4
Recruiting NCT06095518 - DIC Markers and Thrombin Generation Parameters in Patients on ECMO Support: a Pilot Study
Recruiting NCT03965208 - Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation Phase 4
Not yet recruiting NCT05814094 - Red Blood Cell Transfusion in ECMO - A Feasibility Trial N/A
Not yet recruiting NCT06319677 - PK/PD Study of Anti-Infective Drugs in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation Treatment
Completed NCT05338593 - Therapy and Outcome of Prolonged Veno-venous ECMO Therapy of Critically Ill ARDS Patients.